Therefore, this phenomenon indicates that G-1 agonist may be a suitable therapeutic candidate to treat GPER-induced obesity and reduce lipid deposition or even alleviate chronic diseases related to obesity, such as diabetes mellitus. This evidence concerns the gene GPER1 and obesity due to melanocortin 4 receptor deficiency.